Home » Psychology news » Experimental drug may extend therapeutic window for stroke

Experimental drug may extend therapeutic window for stroke

July 18, 2012 by

When given at a time that the FDA-approved clot-busting drug therapy tPA (tissue plasminogen activator) is ineffective, the combination of tPA and an experimental compound called 3K3A-APC reduces brain damage, eliminates brain hemorrhaging and improves motor skills in rodents afflicted by stroke.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>